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Abstract
Introduction: Bone is the most common site of breast cancer metastasis, and complications associated with bone
metastases can lead to a significantly decreased patient quality of life. Thus, it is essential to gain a better
understanding of the molecular mechanisms that underlie the emergence and growth of breast cancer skeletal
metastases.
Methods: To search for novel molecular mediators that influence breast cancer bone metastasis, we generated
gene-expression profiles from laser-capture microdissected trephine biopsies of both breast cancer bone
metastases and independent primary breast tumors that metastasized to bone. Bioinformatics analysis identified
genes that are differentially expressed in breast cancer bone metastases compared with primary, bone-metastatic
breast tumors.
Results: ABCC5, an ATP-dependent transporter, was found to be overexpressed in breast cancer osseous
metastases relative to primary breast tumors. In addition, ABCC5 was significantly upregulated in human and
mouse breast cancer cell lines with high bone-metastatic potential. Stable knockdown of ABCC5 substantially
reduced bone metastatic burden and osteolytic bone destruction in mice. The decrease in osteolysis was further
associated with diminished osteoclast numbers in vivo. Finally, conditioned media from breast cancer cells with
reduced ABCC5 expression failed to induce in vitro osteoclastogenesis to the same extent as conditioned media
from breast cancer cells expressing ABCC5.
Conclusions: Our data suggest that ABCC5 functions as a mediator of breast cancer skeletal metastasis. ABCC5
expression in breast cancer cells is important for efficient osteoclast-mediated bone resorption. Hence, ABCC5 may
be a potential therapeutic target for breast cancer bone metastasis.
Introduction
The skeleton is a favored site for breast cancer metastases
due to unique features of the bone microenvironment,
including the presence of growth factors and cytokines
stored within the bone matrix [1]. The emergence of bone
metastases disrupts normal bone homeostasis by perturb-
ing interactions between bone-forming osteoblasts and
bone-resorbing osteoclasts [2]. Breast cancer metastases in
bone have typically been described as osteolytic in nature,
and are associated with excessive bone destruction [3].
This ultimate shift toward bone resorption results from
the ability of tumor cells, either directly or indirectly, to
influence osteoclast differentiation and activity positively
[4,5]. Subsequently, elevated bone resorption releases
latent growth factors and cytokines that are stored in the
bone matrix; these support tumor cell survival and growth
that ultimately lead to further bone destruction [6,7].
Hence, the crosstalk between breast cancer cells and the
bone microenvironment results in a vicious cycle of bone
destruction and increased tumor growth in bone.
Breast tumors are heterogeneous, and cancer cells
with bone-specific metastatic capabilities may preexist in
the primary tumor. Indeed, gene signatures have been
generated that predict whether a primary breast tumor
will relapse to bone or visceral sites of metastasis [8].
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A Src-related signature has also been proposed to segre-
gate primary breast tumors based on their propensity to
relapse to bone [9]. Numerous studies have identified can-
cer intrinsic factors that allow tumor cells to colonize and
thrive in the bone microenvironment. In vivo selected
breast cancer populations, isolated from bone metastases,
have been used to identify unique functional mediators of
bone metastasis [10-13].
These approaches have yielded valuable information
regarding mechanisms involved in the spread, coloniza-
tion, and growth of breast cancer cells in bone. However,
growing evidence reveals discordance between the expres-
sion of specific markers in the primary breast tumor and
those in the corresponding bone metastases [14]. Up to
40% of breast cancer patients displayed discordance in
hormone-receptor expression between the primary tumor
and the associated bone metastases [15,16]. Thus, it is
likely that the bone microenvironment plays a consider-
able role in modulating the gene-expression profiles of
breast cancer cells in emerging bone metastases. Hence, a
number of important mediators of breast cancer skeletal
metastasis will undoubtedly be overlooked in the analysis
of primary breast tumors or breast cancer cells explanted
ex vivo from bone metastases.
To circumvent these limitations, we sought novel
mediators of skeletal metastasis directly in bone meta-
static lesions from breast cancer patients. We applied
laser-capture microdissection to isolate RNA from both
trephine-biopsies of bone metastases and primary breast
tumors. Numerous genes were differentially expressed
between primary breast tumors that later relapsed to bone
and breast cancer bone metastases, including several
members of the ATP-binding cassette (ABC) transporter
family that were overexpressed in the bone metastases
relative to primary tumors. ABCC5 was found to be func-
tionally involved in the formation of breast cancer bone
metastases in two independent cell-based models.
Materials and methods
Primary breast tumor and bone metastases
Unguided or computed tomography (CT)-guided
trephine biopsies were performed on breast cancer
patients with known bone involvement at the Princess
Margaret Hospital (Toronto, ONT, Canada), as
previously described [17]. Biopsy material was immedi-
ately flash frozen and embedded in OCT compound.
All procedures were performed with approval from the
Research Ethics Board at the Princess Margaret Hospi-
tal. Primary breast tumor material was collected from
patients who underwent surgery at the Montreal
General or Royal Victoria Hospital (Montreal, QUE,
Canada). Tumor banking was performed with approval
from the Research Ethics Board of the McGill University
Health Centre under the protocols SDR-99-780 and
SDR-00-966. All patients provided written and informed
consent.
Laser-capture microdissection
Histologic sections of primary breast tumors or bone
metastases were stained with H&E and examined by a
clinical pathologist to identify regions within each
section suitable for laser-capture microdissection
(LCM). Sections (10 μm) were stained and dehydrated
by using a HistoGene LCM Frozen Section Staining Kit
(Cat KIT0401; Applied Biosystems, Carlsbad, CA, USA).
Clusters of invasive mammary epithelial cells were identi-
fied and selected by using an ArcturusXT Microdissection
System powered by ArcturusXT software v.1.1 (Applied
Biosystems, Carlsbad, CA, USA). Breast cancer cells were
captured by using an infrared laser adjusted to a diameter
of 20 μm, laser power set to 65 mW and a duration of 20
msec, and pulsed through CapSure HS LCM Caps (Cat.
LCM0214; Applied Biosystems, Carlsbad, CA, USA). The
beam was passed over the sample to be collected with an
overlap of 30% for each specimen. RNA was extracted
from the microdissected cells by using a PicoPure RNA
Extraction Kit (Cat. KIT0204; Applied Biosystems,
Carlsbad, CA, USA) according to the manufacturer’s
instructions. RNA integrity and quantity was evaluated by
using a 2100 Bioanalyzer platform (Agilent Technologies,
Santa Clara, CA, USA).
RNA amplification, labeling, and hybridization to Agilent
microarray chips
Total RNA (1 to 2.5 ng) from microdissected material
was subjected to two rounds of linear amplification by
using a RiboAmp HSPlus Amplification Kit (Cat. KIT0525;
Applied Biosystems, Carlsbad, CA, USA), following the
manufacturer’s protocol. Profiles of resulting amplified
RNA (aRNA) were assessed by using a 2100 Bioana-
lyzer (Agilent Technologies, Santa Clara, CA, USA).
The aRNA samples (5 μg) were conjugated to Cy3 dye by
using an Arcturus Turbo Labeling Kit (Cat. KIT0609;
Applied Biosystems, Carlsbad, CA, USA). Universal
human reference RNA (Stratagene) was amplified by
using the same procedure and labeled with Cy5 dye (Cat,
KIT0619; Applied Biosystems, Carlsbad, CA, USA). RNA
concentration and dye incorporation was measured by
using a Nanodrop ND-1000 UV-VIS spectrophotometer.
Labeled RNA (0.825 μg) was then hybridized to 44K
whole human genome microarray gene-expression chips
(Cat. G4112F; Agilent Technologies, Santa Clara, CA,
USA) by using a Gene Expression Hybridization Kit (Cat.
5188-5242; Agilent Technologies, Santa Clara, CA, USA)
at 65°C for 17 hours according to the manufacturer’s
instructions. Microarray chips were washed, dried, and
immediately scanned on a Microarray Scanner Model
G2505B (Agilent Technologies, Santa Clara, CA, USA) by
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using Agilent Scanner Control Software vA7.0.1 (Agilent
Technologies, Santa Clara, CA, USA).
Gene-expression analysis
Microarray data were extracted by using Feature Extrac-
tion Software v. 9.5.3.1 (Agilent Technologies, Santa
Clara, CA, USA). The raw data were then normalized,
and differential expression was performed by using the
LIMMA package in R/bioconductor [18]. Specifically,
the arrays were normalized by using normexp back-
ground correction, loess within array, and quantile
between array normalization. The P values for differential
expression were adjusted for multiple testing. Candidate
gene lists were generated by filtering the data on the basis
of more than twofold difference in expression between
bone metastases and primary breast tumors. The microar-
ray data can be accessed through the GEO repository (ID
GSE39494) [19].
Real-time quantitative reverse-transcription polymerase
chain reaction
RNA obtained after two rounds of amplification was quan-
tified by using Quant-iT RiboGreen RNA Reagent based
on the manufacturer’s protocol (Cat. R11491; Invitrogen,
Grand Island, NY, USA). Total RNA (25 ng) was con-
verted to cDNA by using a Transcriptor Reverse Tran-
scriptase kit (Cat. 048970300001; Roche, Laval, QUE,
Canada) in accordance with the manufacturer’s protocol.
After reverse transcription, samples were subjected to
real-time polymerase chain reaction (PCR) analysis by
using SYBR Green PCR Master Mix (Cat. 04887352001;
Roche, Laval, QUE, Canada). Primers were designed by
using OligoPerfect software (Invitrogen, Burlington, ONT,
Canada) in the region of the target gene surrounding the
Agilent probes, at a concentration of 0.5 μM. PCRs were
performed on a LightCycler 480 system (Roche, Laval,
QUE, Canada) under the following conditions: preincuba-
tion step (95°C for 10 minutes), 45-cycle amplification
sequence (95°C for 10 seconds, 53°C for 10 seconds, 95°C
for 6 seconds) and a melting step (95°C for 5 seconds, 65°
C for 1 minute). A complete list of primer sequences can
be found in the Supplementary Information. Results were
analyzed with the absolute quantification method by using
the second derivative maximum method feature of Light-
Cycler 480 Software v. 1.5.0 SP4 (Roche, Laval, QUE,
Canada).
Immunohistochemistry
OCT-embedded primary breast tumors and bone trephine
biopsies were sectioned (10 μm) and fixed in 2% parafor-
maldehyde. The sections were blocked with 2% BSA and
5% normal goat serum (NGS) and subsequently incubated
overnight at 4°C with a primary antibody directed against
ABCC5 (1:25; clone M5I-10). This monoclonal antibody
was generated in Dr. Scheffer’s laboratory (Amsterdam,
The Netherlands) after injection of a bacterial fusion
protein containing the N-terminal region of mouse
ABCC5. The antibody recognizes mouse ABCC5 but also
reacts strongly with the human orthologue. The sections
were then incubated with Biotin-conjugated secondary
antibody and developed with 3-3-diaminobenzidine-
tetrahydrochloride (DAB). A standard hematoxylin
counterstain was performed to demarcate cellular nuclei.
Primary mammary tumors and hindlimbs were excised
from mice and fixed overnight in 4% paraformaldehyde.
Bones were decalcified in a solution of 14.5% ethylene-
diaminetetraacetic acid (EDTA) and 15% glycerol for
4 weeks. Tissues were then paraffin embedded and
sectioned. Sections (5 μm) were deparaffinized and stained
with a freshly prepared tartrate-resistant acid phosphatase
(TRAP) staining solution (naphthol AS-TR Phosphate, fast
blue RR salt, and sodium tartrate). Slides were scanned by
using a Scanscope XT digital slide scanner (Aperio, Vista,
CA, USA) and analyzed with Imagescope software
(Aperio, Vista, CA, USA). The number of TRAP-positive
cells within breast cancer lesions in bone was counted
manually and is presented as the number of osteoclasts
per square millimeter of tumor mass.
Immunoblotting
Human and mouse cell lines were lysed in TNE lysis
buffer, as previously described [20]. Total protein concen-
trations were determined with the Bradford Protein Assay
(Cat. 500-006; Bio-Rad Laboratories, Mississauga, ONT,
Canada) and 20 to 50 μg of protein was separated with
sodium dodecylsulfate polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred to polyvinylidene fluoride
(PVDF) membranes (Cat. IPVH00010; Millipore, Billerica,
MA, USA). The membranes were blocked in 5% wt/vol
nonfat dry milk containing 0.1% Tween and incubated
with the following primary antibodies: ABCC5 (1:100 dilu-
tion; M5I-10) and a-tubulin (1:20,000 dilution; Cat.
T9026; Sigma, Oakville, ONT, Canada). The blots were
then incubated with horseradish-peroxidase-conjugated
secondary antibodies, and proteins were visualized with an
enhanced chemiluminescence detection system (Cat.
34080; Pierce, Nepean, ONT, Canada).
DNA constructs
Short-hairpin RNA (shRNA) sequences targeting the
human and mouse ABCC5 mRNA, as well as the
scrambled control sequence, were designed by using
the RNAi central website at Cold Spring Harbor
Laboratories [21]. The sequences of the shRNAs used
for ABCC5 knockdown are as follows (target sequence
denoted in bold text: h, human; m, mouse): hABCC5
sh: TGC TGT TGA CAG TGA GCG ACC TCA AAG
TCT GCA ACT TTA ATA GTG AAG CCA CAG
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ATG TAT TAA AGT TGC AGA CTT TGA GGG
TGC CTA CTG CCT GGA; mabcc5 sh1: TGC TGT
TGA CAG TGA GCG ACC TCA TCC TGT CCT
GCT GAA ATA GTG AAG CCA CAG ATG TAT
TTC AGC AGG ACA GGA TGA GGG TGC CTA
CTG CCT CGG A; mabcc5 sh2: TGC TGT TGA CAG
TGA GCG CCC TGA CTA TGG CAT TCA AGA
ATA GTG AAG CCA CAG ATG TAT TCT TGA
ATG CCA TAG TCA GGA TGC CTA CTG CCT
CGG A; scrambled sh: TGC TGT TGA CAG TGA
GCG AAG TCC ATA CTT AGT CGA TAG ATA
GTG AAG CCA CAG ATG TAT CTA TCG ACT
AAG TAT GGA CTC TGC CTA CTG CCT CGG A.
These sequences were PCR amplified, digested, and
cloned into the LMP vector as XhoI/EcoRI fragments
by following published instructions [22].
Cell culture and in vitro osteoclastogenesis assay
Parental MDA-MB-231 breast cancer cells were
obtained from the American Type Culture Collection
and transduced with a triple reporter system, as
previously described [23]. The MDA-MB-231-derived
bone metastatic (1833-BM1) and lung metastatic (4175-
LM2) populations were derived as described previously
[10,24]. Human breast cancer cell lines were cultured in
DMEM supplemented with 10% fetal bovine serum and
MEM Nonessential Amino Acids (1X), gentamycin, and
amphotericin B. The 4T1 murine mammary carcinoma
cell line was obtained from the American Type Culture
Collection. Nonmetastatic 67NR and lung-metastatic
66cl4 murine mammary carcinoma cell lines [25]
were kindly provided by Dr. Fred Miller (Barbara Ann
Karmanos Cancer Institute, Detroit, MI, USA) and cul-
tured in DMEM supplemented with 10% fetal bovine
serum, 10 mM HEPES, 1 mM sodium pyruvate, 1.5 g/L
sodium bicarbonate, gentamycin, and amphotericin B.
For the in vitro osteoclastogenesis assay, 5 × 105 4T1-
derivative cells were plated in 10-cm cell-culture dishes.
The following day, media were changed to DMEM
supplemented with 10% fetal bovine serum and subse-
quently conditioned for 48 hours. Protocols used to estab-
lish primary osteoclast cultures from BALB/c mice were
performed in accordance with the McGill University
guidelines established by the Canadian Council on Animal
Care. Bone marrow was collected from tibiae and femurs
of mice (BALB/c, male, 6 weeks old; Charles River,
Wilmington, MA, USA), as described previously [26], and
cultured in 75-cm2 tissue culture flasks (15 × 106 cells per
flask) in a-minimal essential medium supplemented with
10% fetal calf serum, penicillin, streptomycin, and 25 ng/
ml of human recombinant macrophage-colony stimulating
(M-CSF) factor (Cat. 300-25; PeproTech, Inc.). On day 1,
nonadherent cells were collected, plated at 5 × 103 cells/
cm2, and supplemented with M-CSF (50 ng/ml) and
recombinant GST-RANKL (100 ng/ml). On day 4, fresh
media with or without RANKL (100 ng/ml) or conditioned
media harvested from 4T1-derivatives (10%) were added
to the cultures. M-CSF (50 ng/ml) was present in all
conditions tested. On day 6, cells were fixed with 4%
paraformaldehyde (10 minutes), washed with phosphate-
buffered saline, and stained for tartrate-resistant acid
phosphatase (TRAP) (Cat. 387A-KT; Sigma, Oakville,
ONT, Canada).
Left cardiac ventricle injections
Female SCID/beige and BALB/c mice (4 to 6 weeks old)
were purchased from Charles River Laboratories.
The animals were housed in facilities managed by the
McGill University Animal Resources Centre. All animal
experiments were conducted under a McGill University-
approved Animal Use Protocol in accordance with
guidelines established by the Canadian Council on
Animal Care. Breast cancer cells were harvested from
subconfluent cultures and resuspended in sterile PBS.
Mice were anesthetized with isofluorane, and 1 × 105
human or mouse breast cancer cells, in a volume of
100 μl, were injected into the left cardiac ventricle by using
26G needles [12]. A successful injection was distinguished
by the pumping of arterial blood into the syringe during
the injection procedure and confirmed by a uniform lumi-
nescent signal throughout the entire animal body after
1833-BM1 cell inoculation.
In vivo bioluminescent imaging
Tumor outgrowth within skeletal sites of mice injected
with 1833-BM1 breast cancer cells was monitored by
using an IVIS 100 (Caliper Life Sciences, Hopkinton, MA,
USA) bioluminescence imaging system, as previously
described [27]. The resulting data were normalized to the
signal generated by the initial cell inoculum, which was
measured immediately after cardiac injection. Total meta-
static burden was measured by setting a uniform scale for
each group of mice, outlining regions of interest around
all luminescence signals in the body and summing them.
X-ray microcomputed tomography (μCT) imaging
At the end of the cardiac-injection experiments (21 days
for 1833-BM1 and 13 days for the 4T1 models), mice were
anesthetized and immobilized with tape in the imaging
tube of a Skyscan 1178 μCT. All images were obtained
with an x-ray source operating at 50 kV (1833-BM1) or
45 kV (4T1) and 615 mA, with an exposure time of
480 msec. Animals were rotated through 180 degrees at a
rotation step of 1.26 degrees (1833-BM1 cells) and 0.9
degrees (4T1 cells). Cross-section images from tomogra-
phy projection images were reconstructed by using the
NRecon program package v.1.6.4.7 (SkyScan, Kontich,
Belgium). Reconstruction parameters, including smoothing
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(1), ring artefacts reduction (4), and beam-hardening
correction (30%), were fixed for all the samples. The
dynamic image range was defined between 0 and 0.045 for
all the samples. Bone alignment was adjusted in all speci-
mens by using DataViewer v.1.4.3.2 (SkyScan, Kontich,
Belgium). Bone volume was determined in 3D by using
CTAn software v.1.11.8.0 (SkyScan, Kontich, Belgium). In
brief, for each bone, a volume of interest (VOI) was deter-
mined starting under the growth plate and extending 20
(femur) and 25 (tibia) sections below the diaphysis.
For each model, the VOI was designed by drawing user-
defined polygons on the 2D sections that encompass the
bone of interest. In the binary image mode, the histogram
was set at minimum 100 to maximum 255 for a given
dataset for each specimen. Each 3D model was visualized
by using CTvox v.2.3 (SkyScan, Kontich, Belgium). The
absolute bone volume was determined for each piece of
bone and expressed in cubic millimeters. Control groups,
including uninjected mice of similar strain and age as the
experimental animals, were used as reference for normal
bone volume. The degree of bone destruction was deter-
mined as percentage difference between the average bone
volumes in experimental groups compared with those in
the appropriate control cohorts.
Statistical analysis
Statistical significance values for RT-qPCR expression,
whole body luminescence, μCT bone volumes, and osteo-
clast assays were obtained by performing a two-sample
variance two-tailed Student t test.
Supplemental Materials and Methods can be found as
Additional file 1.
Results
Laser-capture microdissection of human breast cancer
bone metastases
To generate gene-expression profiles of primary human
breast cancer bone metastases and primary breast cancers,
we selected five fresh-frozen samples for each group (see
Additional file 2, Additional file 3). For this study, the pri-
mary breast tumors were not patient-matched to the bone
metastases.
The bone metastases were obtained from breast cancer
patients who had consented to undergo unguided or
CT-guided trephine biopsies. To ensure that the biopsy
material contained breast cancer cells, we performed
co-immunofluorescence staining with both luminal (CK8/
18) and basal (CK5) cytokeratins. Clusters of CK5-positive
epithelial cells were found in all of the bone metastases
used in our analysis, a marker associated with basal-like
breast cancer cells (see Additional file 4, top panels).
However, in three of five samples (BM-001, BB-005, BM-
007), expression of the luminal cytokeratin 8/18 markers
were also detected, suggesting that these breast cancer
cells were of mixed lineage (Additional file 4, middle
panels). A DAPI stain identified the location of all cells in
each section (Additional file 4, bottom panels).
Clusters of invasive epithelial cells were specifically
identified in each sample and subjected to laser-capture
microdissection (LCM) (Figure 1). After RNA extraction,
two rounds of amplification and labeling, gene-expression
profiles of each sample were obtained by using human
whole genome (44K) Agilent microarray chips. Unsuper-
vised clustering using the top 200 most-variable probes
segregated the samples into primary breast tumors and
bone metastases, irrespective of ER, PR, and Her2 status
(data not shown).
Identification of putative molecular mediators of breast
cancer skeletal metastasis
Filtering the differential gene-expression data yielded a
list of 244 overexpressed and 185 underexpressed probes
in breast cancer skeletal metastases compared with
primary breast tumors. After a review of the literature,
118 upregulated and 82 downregulated unique genes
with known or ascribed functions were identified in
bone metastases compared with primary tumors (see
Additional file 5). These genes were further categorized
into distinct functional groups based on their proposed
roles, which included mediators of: transcription, trans-
lation, posttranslational modification, mitochondrial
functions/metabolism, cell-cycle progression, cellular
transport, cytoskeletal organization, cellular adhesion/
migration/invasion, tumor microenvironment, chemo-
taxis, cell differentiation, apoptosis/survival, and other
(see Additional file 6).
A number of genes responsible for cellular migration
and invasiveness were downregulated in bone metastases
compared with primary tumors (NCK2 [28], PHPT1
[29], LIMK1 [30], TESK1 [31], and TMSB10 [32]).
Moreover, a few genes involved in modulation of the
extracellular matrix (ADAMTS4 [33], MMP1 [34],
MMP3 [35], and angiogenesis (MFAP5 [36], SFRP2 [37],
SRPK1 [38], VEGF [39], and CHI3L1 [40]) were found
to be expressed at higher levels in the primary breast
tumors compared with the bone metastases. Our data
support a role for these two gene sets in promoting
local invasion at the primary tumor, which may have
facilitated breast cancer dissemination to distant organs
such as the bone.
Interestingly, the expression of genes (GFRA1, ID1,
ABCG2) implicated in the regulation of hematopoietic
progenitor cells was found to be elevated in bone metas-
tases compared with the primary breast tumors that had
relapsed to bone [41-44]. This finding lends support to the
notion that breast cancer cells may use the endosteal
niche, which preexists within the bone microenvironment,
to colonize the bone [45]. It has been reported that cancer
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cells potentially compete with HSCs for occupancy of
these endosteal niches and represent privileged sites where
cancer cells first establish [46]. Additionally, a number of
prosurvival (BCL2 [47], PPEF2 [48]) and proapoptosis
(BID [49], HEBP2 [50], and PKNOX1 [51]) genes were up-
and downregulated, respectively, in bone metastases com-
pared with primary breast tumors. Importantly, the
expression of well-known pro- (BCL2) and anti-apoptotic
(BID) genes was validated with RT-qPCR (see Additional
file 7, Additional file 8).
Finally, macrophage inhibitory factor (MIF) was found
to be downregulated in breast cancer skeletal metastases
compared with the primary mammary tumors. It has been
shown that MIF promotes breast cancer cell proliferation
[52,53], angiogenesis [54], and survival [55]. However,
although MIF was frequently overexpressed in primary
mammary tumor tissues, its presence was inversely corre-
lated with the nodal spread of breast cancer [56].
A recent study suggested that intracellular MIF levels
are low in aggressive breast cancer cell lines and that
cytosolic MIF expression associates with an increase of
recurrence-free survival patients, whereas extracellular
MIF promotes migration and invasion of breast cancer
cells [57]. Interestingly, MIF was also shown to inhibit
osteoclastogenesis in the in vitro and in vivo assays [58].
Thus, loss of MIF may be required during the formation
of osteolytic bone metastases.
By using RT-qPCR analysis, we were able to validate
the gene-expression changes for several candidates
initially identified with microarray-based gene-
expression profiling (see Additional file 7, Additional
file 8). Intriguingly, several members of the ATP-bind-
ing cassette (ABC) transporter superfamily (ABCA5,
ABCC5, and ABCG2) were consistently overexpressed
in breast cancer bone metastases compared with pri-
mary breast tumors (Additional file 7, Additional file
8). Although a significant body of literature has linked
ABCG2 expression with drug resistance in breast
cancer [59], considerably less is known about ABCA5




























Figure 1 Laser-capture microdissection (LCM) of breast cancer cells. Malignant mammary epithelial cells were isolated from primary breast
tumors (top panels) and bone trephines (bottom panels). The selected regions containing the breast cancer cells were adhered to LCM caps
(right panels). Left panels represent images of slides after completion of LCM, with black arrows indicating the isolated material. The scale bar on
the top left image represents 1,000 μm and applies to all panels.
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ABCC5 is overexpressed in breast cancer bone metastases
and bone metastatic breast cancer cells
Given the availability of antibody reagents, we focused our
attention on ABCC5, a candidate gene that was found to be
significantly overexpressed in breast cancer skeletal metas-
tases relative to primary tumors by both microarray-based
and RT-qPCR methods (Figure 2A). Furthermore, immuno-
histochemical analysis revealed that ABCC5 protein levels
appeared to be enriched in breast cancer bone metastases
compared with primary mammary tumors (Figure 2B).
As a first step to validate functionally a role for ABCC5
in promoting bone metastasis, we interrogated the expres-
sion of ABCC5 in breast cancer cell lines with high bone-
metastatic potential. By using a series of in vivo-selected
MDA-MB-231 breast cancer cell populations that are
metastatic to bone and lung, we demonstrated that
ABCC5 expression was highest in bone metastatic cell
populations (1833-BM1) when compared with lung meta-
static cells (4175-LM2) or the parental MDA-MB-231 cell
line (Figure 3A). We also examined an independent
murine breast cancer series isolated from the same origi-
nal mammary tumor that are either nonmetastatic
(67NR), lung-metastatic (66cl4), or metastatic to multiple
organs, including bone (4T1). We demonstrated that
ABCC5 expression was considerably higher in the bone-
metastatic 4T1 cell line relative to lung-metastatic 66cl4
and nonmetastatic 67NR populations (Figure 4A).
Loss of ABCC5 expression diminishes the formation of
breast cancer bone metastases
To determine whether ABCC5 is important for the ability
of breast cancer cells to metastasize to bone, we stably
diminished ABCC5 expression in bone-metastatic breast
cancer cell lines by using short-hairpin RNAs (shRNAs).
An efficient and stable knockdown was achieved in both
human 1833-BM1 (Figure 3B) and mouse 4T1 (Figure 4B)
breast cancer cell lines relative to the parental cell lines or
populations harboring a scrambled shRNA control.
Importantly, diminished ABCC5 expression in human and
mouse mammary cancer cell lines did not affect their
proliferative properties in vitro or their in vivo growth as
mammary tumors (Additional file 9). However, loss of
ABCC5 expression in the human 1833-BM1 population
resulted in a fourfold reduction in overall bone metastatic
burden after left cardiac ventricle injections, as measured
by bioluminescence imaging (Figure 3C). Whereas the
total number of bone metastases per mouse was similar
in scrambled control and ABCC5 shRNA cohorts
(Figure 3D), the size of the individual lesions was clearly
diminished (Figure 3C). Interestingly, the osteolytic bone-
metastatic lesions arising in mice injected with ABCC5low
1833-BM1 cells were significantly smaller (6% bone
destruction) than were those observed in animals injected
with the scrambled shRNA-expressing population
(16% bone destruction), as measured with volumetric μCT
analysis (Figure 3E).
To confirm this functional role for ABCC5 in promoting
breast cancer metastasis to bone, we analyzed the effects
of reduced ABCC5 expression on the ability of 4T1 breast
cancer cells to form bone metastases after cardiac injec-
tion. Two independent 4T1 populations, each harboring a
unique shRNA targeting ABCC5, and 4T1 cells containing
a scrambled shRNA, were injected into separate cohorts of





















































































































Figure 2 ABCC5 expression is elevated in breast cancer bone
metastases. (A) ABCC5 gene expression was found to be
significantly overexpressed in breast cancer bone metastases (BMs)
compared with primary breast tumors (BTs) that were metastatic to
bone by both Agilent microarray analysis (left panel) and RT-qPCR
(right panel); *P = 0.002; **P = 0.03. (B) Immunohistochemical (IHC)
analysis confirmed that ABCC5 expression was higher in bone
metastases (right panels) compared with primary breast tumors (left
panels). IHC was performed on frozen sections for all the samples,
and the ABCC5 staining intensity is indicated in the lower left
corner of each image. Scale bar in the first panel represents 100 μm
and applies to all images.
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cell-line model, suppression of ABCC5 expression in
mouse breast cancer cell lines did not result in the altera-
tion of the total number of bone metastases per mouse
(Figure 4C). However, μCT analysis revealed that reduced
ABCC5 expression in mouse-derived 4T1 cells resulted in
significantly less (shRNA 1, 26% bone destruction; shRNA
2, 16% bone destruction) bone destruction compared
with the scrambled controls (40% bone destruction)
(Figure 4D). Interestingly, no difference was found in
either the number of spontaneous lung metastases or the
size of the lesions formed by 4T1-derivative breast cancer
cells harboring the ABCC5 knockdown when compared
with cells expressing the scrambled shRNA (see Additional
file 10). Together, these results support an important func-
tional role for ABCC5 in promoting the colonization and
growth of breast cancer cells specifically within the bone.
Proliferation and apoptosis are not affected in mammary
tumors or bone metastases by diminished ABCC5
expression
To investigate potential explanations for the reduction
in the size of osteolytic lesions arising in mice injected
with breast cancer cells engineered to express ABCC5


































































































































Figure 3 ABCC5 promotes the formation of osteolytic bone metastases in MDA-MB-231 human breast cancer cells. (A) ABCC5
expression is appreciably higher in the bone metastatic 1833-BM1 population compared with parental MDA-MB-231 cells and the lung-
metastatic 4175-LM2 population. (B) Immunoblot analysis reveals that ABCC5 expression was efficiently silenced via short-hairpin RNA (shRNA) in
the 1833-BM1 breast cancer cell line. An immunoblot for a-tubulin served as a loading control in panels (A) and (B). (C) Diminished ABCC5
expression in 1833-BM1 cells resulted in reduced formation of skeletal metastases after cardiac injection, as determined by in vivo bioluminescent
imaging. The data and representative images are shown for day 21 after tumor-cell injection (scr shRNA, n = 10; ABCC5 shRNA, n = 8; *P =
0.024). (D) All of the animals developed osteolytic lesions after injection of the breast cancer cells. The number of lesions per animal was
determined by analyzing blinded μCT images. (E) The degree of osteolytic bone destruction was quantified by in vivo μCT imaging. Bone
volume was calculated from reconstructions of defined regions of both the proximal tibia and femur from mice imaged on day 21 after
injection (scr shRNA, n = 20; ABCC5 shRNA, n = 16; **P = 0.041). Controls (n = 10) refers to age-matched females mice that were not injected
with breast cancer cells. Representative images of bone reconstructions are shown.
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indices in both mammary tumors and bone metastases.
In agreement with the observation that reduced ABCC5
levels did not negatively influence primary tumor
growth (Additional file 9), we did not observe statisti-
cally significant differences in the percentage of Ki67-
positive nuclei in primary tumors derived from 1833-
BM1 or 4T1 cells, possessing normal or shRNA-reduced
levels of ABCC5 (see Additional file 11A and B). Inter-
estingly, no differences in proliferation were observed in
bone metastases that formed in mice injected with
1833-BM1- or 4T1-derived breast cancer populations,
which possessed diminished ABCC5 expression or
normal endogenous levels of ABCC5 (Additional file
11C and D).
To determine whether loss of ABCC5 was associated
with elevated levels of apoptosis, we performed immu-
nohistochemical staining for cleaved caspase-3 in both
mammary tumors and bone metastases that arose in
mice injected with 1833-BM1- or 4T1-derived breast
cancer populations. Diminished ABCC5 expression did
not result in elevated apoptosis in either end-stage
mammary tumors (Additional file 12A and B) or end-









































































































Figure 4 ABCC5 promotes the formation of osteolytic bone metastases induced by 4T1 murine breast cancer cells. (A) ABCC5
expression is considerably elevated in the highly metastatic mouse breast cancer cell line 4T1, which exhibits bone metastatic activity, when
compared with a less-metastatic 66cl4 (lung) and nonmetastatic 67NR populations. (B) ABCC5 expression was stably silenced by using two
independent short-hairpin RNAs (sh 1, sh 2) in 4T1 breast cancer cells, as demonstrated with immunoblot analysis, when compared with parental
4T1 cells (4T1p) and a scrambled shRNA control (Scr shRNA). (C) All of the animals had osteolytic lesions after breast cancer cell injections. The
number of lesions per animal is indicated and was established by examining blinded μCT images. (D) Reduction in ABCC5 levels in 4T1 breast
cancer cells results in the diminished formation of osteolytic bone metastases after cardiac injection (scr shRNA, n = 19; abcc5 shRNA 1, n = 16;
abcc5 shRNA 2, n = 19; *P = 0.015; **P < 0.001). Controls (n = 18) refers to age-matched female mice that were not injected with breast cancer
cells. The degree of osteolytic bone destruction in the hindlimbs was quantified by in vivo μCT imaging. Bone volume of defined regions of
both the proximal tibia and femur is shown for animals imaged on day 21 after injection. Representative images of bone reconstructions are
shown.
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Reduced ABCC5 levels in breast cancer cells correlate
with reduced osteoclast numbers within bone metastatic
lesions and diminished in vitro osteoclastogenesis
To better define the mechanisms responsible for
impaired bone metastasis in mice injected with the
ABCC5-knockdown breast cancer cell populations, we
examined the density of osteoclasts present within lytic
lesions formed by the MDA-MB-231 and 4T1-derived
cells. Representative bone sections were stained for tar-
trate resistant acid phosphatase (TRAP), an osteoclast-
specific marker. The number of TRAP-positive cells was
significantly reduced by 2.7 times in the 1833-BM1 lesions
expressing the ABCC5 shRNA compared with the bone
metastases harboring the scrambled shRNA control (Fig-
ure 5A). Two independent 4T1-derived populations, each
expressing a unique shRNA-targeting abcc5, also showed
a 1.8- and 4.1-fold reduction in TRAP-positive cells when
compared with 4T1 breast cancer cells harboring the
scrambled shRNA control (Figure 5B). Together, these
data demonstrate that loss of ABCC5 function in breast
cancer cells results in decreased osteoclast numbers within
bone-metastatic lesions. These results are in agreement
with the diminished capacity to form osteolytic metastases
that is exhibited by breast cancer cells with diminished
ABCC5 expression. Our data support a role for ABCC5 in
promoting the specific growth of breast cancer cells within
the bone microenvironment through a mechanism that
favors osteoclast formation and/or function.
Further to investigate the potential role of tumor-
intrinsic ABCC5 in promoting osteolytic lesion formation,
we performed an in vitro osteoclast differentiation assay.
Primary osteoclast cultures were established from murine
bone marrow and primed with macrophage colony-
stimulating factor (M-CSF) and receptor activator of
nuclear factor -B ligand (RANKL). The osteoclast precur-
sors were subsequently stimulated with conditioned media
from the 4T1-derived populations, which exhibited the
most-pronounced difference in osteoclast numbers
between control and ABCC5 knockdown breast cancer
cells in vivo (Figure 5). Intriguingly, the number of multi-
nucleated TRAP-positive osteoclasts was reduced by 1.3
and 1.6 times when osteoclast precursors were cultured in
media collected from 4T1 harboring two independent
abcc5-specific shRNAs, when compared with the
scrambled shRNA control (Figure 6).
Discussion
The vicious cycle of bone-metastasis formation argues that
breast cancer cells colonizing the bone are influenced by
growth factors that are stored in the bone matrix; these
are released during bone resorption [1,2]. These influences
predict that breast cancer bone metastases will differ in
their gene-expression profiles from primary breast tumors.
To evaluate gene-expression profiles of in situ bone
metastases from breast cancer patients, we performed
laser-capture microdissection (LCM) on trephine biopsies
and compared them with profiles obtained from LCM
material of primary breast tumors. Numerous genes were
differentially expressed between primary breast tumors
with known relapse to bone and breast cancer bone
metastases and were categorized according to their known
or proposed functions.
Intriguingly, three members of the ATP-binding cassette
(ABC) transporter family (ABCA5, ABCC5, ABCG2) were
overexpressed in breast cancer bone metastases compa-
red with primary tumors that are metastatic to bone
(Additional file 7 and Additional file 8). The human gen-
ome encodes 49 ABC genes that are arranged in seven
subfamilies designated A to G [60]. These genes encode
ATP energy-dependent molecular pumps that transport
substrates across membranes, either in or out of cells or
into cellular vesicles, against their electrochemical gradient
[61]. Consistent with the role of these transporters in the
excretion of diverse compounds, their expression
(ABCG2, ABCA1, ABCA7, ABCG1, and ABCG5) has
been found in lactating mammary epithelium [62,63].
Furthermore, the ABC transporters (ABCG2, ABCB1)
have been proposed to be expressed by quiescent cancer
stem cells, which allows them to survive cytotoxic or
targeted therapies leading to relapse [64].
We focused on ABCC5 (MRP5) as a candidate mediator
of breast cancer skeletal metastases because we validated
its expression in bone metastases at both the mRNA and
protein levels (Figure 2). ABCC5 represents a membrane-
spanning protein belonging to the C subfamily of the ABC
transporters, with the ability to transport endogenous
cyclic nucleotides [65]. One concern associated with our
identification of ABC transporters was the possibility that
these proteins were upregulated as a consequence of the
patient’s treatment history rather than any specific role
that they might play in the establishment of bone metas-
tases [66,67]. To address this possibility, we examined
ABCC5 expression in breast cancer cell populations that
exhibit a bone-metastatic phenotype. We first used a series
of in vivo selected MDA-MB-231 cell lines with different
organ-specific metastatic potential and found that ABCC5
was most highly expressed in the bone-metastatic
MDA-MB-231 cells when compared with the parental and
lung-tropic MDA-MB-231 cells (Figure 3A).
We next determined the level of ABCC5 expression in
mouse-derived breast cancer cells with differential
metastatic abilities. Consistent with the result in MDA-
MB-231 cells, the highly metastatic 4T1 population,
which is highly metastatic to bone and other sites,
exhibited considerably higher ABCC5 expression in
comparison with lung-only metastatic 66cl4 and nonme-
tastatic 67NR populations (Figure 4A). These data reveal
that ABCC5 expression is highest in breast cancer cells
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Figure 5 Loss of ABCC5 in breast cancer cells results in diminished osteoclast numbers within osteolytic lesions. (A) Quantification of
TRAP-positive osteoclasts within osteolytic lesions formed by human-derived 1833-BM1 cells (scr shRNA, n = 7; ABCC5 shRNA, n = 7; *P = 0.03).
Representative images are shown for each group. The scale bars represent 100 μm and apply to both images. (B) Quantification of TRAP-positive
cells present within bone metastases formed in mice injected with 4T1-derived populations (scr shRNA, n = 8; abcc5 shRNA 1, n = 6; abcc5
shRNA 2, n = 5; **P < 0.001; ***P < 0.001). Representative images are shown for each group. The scale bar in the upper image represents 100
μm and applies to all images.
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that display enhanced bone-metastatic phenotypes,
under conditions in which no treatments (antiestrogens,
chemotherapy, or bisphosphonates) were used. Thus, it
is conceivable that elevated ABCC5 expression is
selected for because of a particular function that enables
breast cancer cells to colonize the bone microenviron-
ment efficiently.
The physiological functions of ABCC5 are, at present,
poorly defined. It was reported that this protein serves
as an efflux pump for intracellular cyclic guanosine
monophosphate (cGMP) and, to a lesser degree, cyclic
adenosine monophosphate (cAMP) [65]. A growing
body of literature suggests that elevated intracellular
cGMP levels result in reduced breast cancer cell prolif-
eration, ultimately triggering apoptosis via activation of
protein kinase G (PKG) [68-70]. Nitric oxide and
natriuretic peptides, which serve as activators of soluble
and transmembrane guanylyl cyclises, respectively, are
abundant in bone and exert complex effects on bone
cells, bone turnover, and bone formation [71]. Thus, we
reasoned that upregulation of a cGMP efflux pump
could be advantageous for breast cancer growth and
survival in the bone microenvironment. Diminished
ABCC5 expression resulted in a significant reduction in
the size of osteolytic lesions formed by both 1833-BM1
and 4T1 breast cancer cell models when compared with
controls. However, this reduction was not a reflection of
general alterations in breast tumor cell growth (Addi-
tional file 9). Consistently, no change in breast cancer
cell proliferation, in either primary breast tumors or
bone metastases, was noted when ABCC5 was knocked
down compared with controls (Additional file 11).
Moreover, the removal of ABCC5 did not result in
elevated rates of apoptosis in either primary tumors or
breast cancer bone metastases, as assessed with immu-








































Positive Control (PC) Negative Control (NC)
4T1 CM – Scr shRNA 4T1 CM – abcc5 sh#1 4T1 CM – abcc5 sh#2
Figure 6 Loss of ABCC5 in breast cancer cells results in diminished osteoclast differentiation in vitro. Mouse bone marrow cells were
primed with M-CSF and RANKL for 3 days and then cultured for 2 days untreated (negative control, NC), RANKL treated (positive control, PC), or
conditioned media from 4T1-derived populations (scrambled shRNA (Scr), abcc5 shRNA 1, and abcc5 shRNA 2). Osteoclasts were counted for
each condition, and the results are expressed as a percentage of the osteoclast number in the positive control. The data are presented as
averages of five independent experiments (*P < 0.05). Representative images are presented for each group. The scale bar in the first image
represents 100 μm and applies to all images.
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Finally, we did not observe any differences in breast
cancer cell apoptosis in response to a stimulator of
cGMP production (A-350619 hydrochloride) in control
or ABCC5 knockdown cells (data not shown). These
observations suggest that ABCC5 does not promote
breast cancer proliferation and survival in end-stage
bone metastases through a mechanism that involves
cGMP efflux and reduced PKG activation.
Elevated cGMP levels have also been shown to modulate
the expression of matrix metalloproteinases (MMPs),
although this regulation appears complex. Some studies
suggest that elevated cGMP levels can induce the expres-
sion of MMP-2 and MMP-9 [72,73], whereas others argue
that MMP-9 expression or secretion is suppressed by
increasing cGMP concentrations [74,75]. Whether breast
cancer cells that express ABCC5, and thus maintain low
cytoplasmic cGMP levels through active efflux, are
associated with elevated MMP-9 expression or secretion
requires further investigation.
One interesting result was the observation that the den-
sity of TRAP-positive osteoclasts was reduced in lesions
formed by breast cancer cells harboring reduced ABCC5
levels compared with bone metastases arising from control
cells. Consistent with these observations, conditioned
media from ABCC5 knockdown cells were less efficient in
inducing in vitro osteoclast differentiation compared with
media collected from cells harboring scrambled shRNA.
It should be noted that the diminishment of osteoclasto-
genesis was not complete, and, in the case of one ABCC5
shRNA (shRNA 1), only trended toward a decrease in
osteoclastogenesis. These results raise the possibility that
the substrate of ABCC5 might directly influence osteoclast
differentiation; however, it is also conceivable that the
cargo that is pumped out of breast cancer cells by ABCC5
indirectly influences osteoclastogenesis through an inter-
mediate cell type present in the bone microenvironment.
Previous studies showed that high levels of cGMP can
negatively regulate the ability of osteoclasts to resorb
bone, disrupting their attachment to the bone surface and
preventing efficient secretion of HCl [76,77]. However, an
important phase of the bone resorption mediated by
osteoclasts is their ability to break the sealing zone, detach
from the bone surface, migrate to a new area of bone, and
reinitiate bone resorption. Indeed, nitric oxide or cGMP
analogues have been shown to stimulate osteoclast migra-
tion [78]. Thus, it is conceivable that locally elevated levels
of cGMP, by virtue of a growing breast cancer metastasis,
could contribute to enhanced osteoclast migration.
The reduction of ABCC5 could diminish cGMP efflux,
leading to impaired osteoclast motility and decreased bone
resorption. This hypothesis might explain the specific
requirement for ABCC5 expression in breast cancer cells
that metastasize to the bone. Alternatively, an as-yet-
unidentified ABCC5 cargo may be responsible for
enhanced osteoclast differentiation and motility that leads
to the formation of osteolytic breast cancer metastases in
bone.
Conclusions
We identified ABCC5 as a gene that is overexpressed in
breast cancer bone metastases compared with primary
breast tumors. This protein was also highly expressed in
human and mouse cells breast cancer cell lines that are
highly metastatic to bone. Finally, ABCC5 was function-
ally validated in in vivo models to be an important med-
iator in breast cancer outgrowth in this organ. ABCC5
functions to promote osteolytic bone destruction
through the recruitment and enhanced formation of
osteoclasts. Hence, ABCC5 is a novel candidate media-
tor of breast cancer bone metastasis, which may be a
potential target for the development of treatment for
this detrimental disease.
Additional material
Additional file 1: Supplemental Materials and Methods. This file
contains the experimental procedures not presented in the main text.
Additional file 2: Supplemental Table 1. Clinical data of the breast
cancer samples. This table describes the clinical data of the breast
cancer samples used in the study.
Additional file 3: Figure S1: Histologic appearance of primary breast
tumors and breast cancer bone metastases. All of the samples used
for the study were reviewed by a breast pathologist. Bone metastases
samples primarily consist of the malignant mammary epithelium and
stroma. The primary tumor material displays more complexity. All of the
primary breast tumor samples contained invasive epithelial cells and
stroma. In addition, some of the samples included ductal carcinoma in
situ (DCIS) as well as normal and hyperplastic mammary ducts. Scale bar
represents 50 μm and applies to all the images.
Additional file 4: Figure S2: Human breast cancer metastases
express basal keratins or coexpress basal and luminal keratins. The
expression of cytokeratin 8/18 (CK8/18) and cytokeratin 5 (CK5) in breast
cancer bone metastases was assessed with immunofluorescence. All of
the bone metastases stained positive for the myoepithelial marker CK5,
implying their basal-like phenotype. Three of five bone metastases also
stained positive for the luminal marker, CK8/18. The images were taken
on a confocal microscope under the 63× objective. The scale bar
represents 20 μm and applies to all the images.
Additional file 5: Microarray data. This is a list of differentially
expressed probes between bone-trephine biopsies from breast cancer
patients and primary breast tumors metastatic to skeleton.
Additional file 6: Figure S3: Categories of genes that are
differentially expressed in the breast cancer bone metastases
compared with the primary breast tumors that were metastatic to
bone. Application of filter criteria described in Materials and Methods
resulted in a list of 244 overexpressed and 185 underexpressed probes in
breast cancer skeletal metastases compared with primary breast tumors.
This list was further condensed to 118 upregulated and 82
downregulated genes when only unique genes with described functions
were considered. These genes were subcategorized on the basis of their
known functions.
Additional file 7: Figure S4: Agilent gene-expression data of genes
selected for RT-qPCR validation. A subset of candidate genes that
were differentially expressed between breast cancer bone metastases
and primary tumors is shown. Several members of the ATP-binding
cassette (ABC) transporter family were found to be overexpressed in
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breast cancer bone metastases relative to the primary tumors metastatic
to bone.
Additional file 8: Figure S5: RT-qPCR validation of genes that are
differentially expressed between primary breast tumors and breast
cancer bone metastases. The Agilent gene-expression data were
validated at the message level with RT-qPCR. A high degree of
concordance between the Agilent microarray expression data (Additional
File 7, Figure S4) and the RT-qPCR analysis was observed.
Additional file 9: Figure S6: Reduced ABCC5 expression does not
alter growth characteristics of MDA-MB-231 human or 4T1 mouse
breast cancer cells. (A) In vitro growth curves for 1833-BM1 cells
expressing either scrambled (Scr shRNA) or ABCC5 specific short-hairpin
RNAs (ABCC5 shRNA) are shown. The average of three independent wells
is presented for each time point. The error bars denote the standard
error of the mean (SEM). (B) Tumor growth curves after mammary fat
pad injection are shown. Mammary tumor growth was measured
biweekly for 29 days in mice injected with 1833-BM1 expressing Scr
shRNA (n = 14) or ABCC5 shRNAs (n = 16). Error bars signify the SEM for
each time point. (C) In vitro growth curves are shown for 4T1-derived
breast cancer cells expressing either scrambled (Scr shRNA) or ABCC5
specific short-hairpin RNAs (ABCC5 shRNA). The average of three
independent wells is presented for each time point. The error bars
denote the SEM. (D) Growth of 4T1-derived mammary tumors in
syngeneic mice after mammary fat pad injection is shown. Mammary
tumor growth was measured biweekly for 36 days in mice injected with
4T1 cells expressing Scr shRNAs (n = 10) or two independent ABCC5
shRNAs [shRNA 1 (n = 10) or shRNA 2 (n = 10)]. Error bars signify the
SEM for each time point.
Additional file 10: Figure S7: Reduced ABCC5 expression does not
alter spontaneous lung metastasis burden in mice bearing 4T1-
derived mammary tumors. Lungs from mice bearing 4T1 tumors
expressing Scr shRNA (n = 5) or two independent ABCC5 shRNAs (shRNA
1 (n = 5) or shRNA 2 (n = 5)) extracted at end point and stained with
H&E. The number of lesions per lung (A) and the total lesion area per
lung (B) were analyzed. The error bars represent the standard error of
the mean and apply to all the graphs.
Additional file 11: Figure S8: Reduced ABCC5 expression does not
alter the proliferative index of human MDA-MB-231 or mouse 4T1
primary tumors nor bone metastases at end stage. (A) Primary
tumors derived from mice injected with 1833-BM1 cells expressing Scr
shRNA (n = 5) or ABCC5 shRNA (n = 5) on day 29 after injection were
stained against Ki67. (B) Primary tumors derived from mice injected with
4T1 cells expressing Scr shRNAs (n = 5) or two independent ABCC5
shRNAs (shRNA1 (n = 5) or shRNA2 (n = 5)) on day 36 after injection
were stained against Ki67. (C) Hindlimbs with bone metastases formed
from the intracardiac injection of 1833-BM1 cells expressing Scr shRNA (n
= 5) or ABCC5 shRNA (n = 5) on day 21 after inoculation were stained
against Ki67. (D) Hindlimbs with bone metastases formed from the
intracardiac injection of 4T1 cells expressing Scr shRNAs (n = 5) or two
independent ABCC5 shRNAs (shRNA 1 (n = 5) or shRNA 2 (n = 5)) on day
13 after inoculation were stained against Ki67. Proliferation is expressed
as the percentage of Ki67-positive nuclei. The error bars represent the
standard error of the mean and apply to all the graphs.
Additional file 12: Figure S9: Reduced ABCC5 expression does not
alter the apoptosis of human MDA-MB-231 or mouse 4T1 primary
tumors or bone metastases at end stage. (A) Primary tumors derived
from mice injected with 1833-BM1 cells expressing Scr shRNA (n = 5) or
ABCC5 shRNA (n = 5) on day 29 after injection were stained against
cleaved caspase-3. (B) Primary tumors derived from mice injected with
4T1 cells expressing Scr shRNAs (n = 5) or two independent ABCC5
shRNAs (shRNA 1 (n = 5) or shRNA 2 (n = 5)) on day 36 after injection
were stained against cleaved caspase-3. (C) Hindlimbs with bone
metastases formed from the intracardiac injection of 1833-BM1 cells
expressing Scr shRNA (n = 5) or ABCC5 shRNA (n = 5) on day 21 after
inoculation were stained against cleaved caspase-3. (D) Hindlimbs with
bone metastases formed from the intracardiac injection of 4T1 cells
expressing Scr shRNAs (n = 5) or two independent ABCC5 shRNAs
(shRNA1 (n = 5) or shRNA2 (n = 5)) on day 13 after inoculation were
stained against cleaved caspase-3. Apoptosis is expressed as the number
of cleaved caspase-3-positive nuclei per 1,000 cells. The error bars
represent the standard error of the mean and apply to all the graphs.
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